Patients with lung cancer in the thoracic department
Conditions
Interventions
Plain bupivacaine with dexmedetomidine group:Administer 105 mg of plain bupivacaine + 0.5 µg/kg of dexmedetomidine
Liposomal bupivacaine group:Administer 93 mg of bupivacaine liposome + 25 mg of regular bupivacaine.
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Eligible participants are adults aged between 18 and 80 years old with American Society of Anesthesiologists (ASA) physical status classification of I to III. 2. All patients are scheduled to undergo elective thoracoscopic lung resection surgery, including wedge resection, segmentectomy or lobectomy, under general anesthesia, with either single-port or three-port approach, and the estimated operation time does not exceed 4 hours. 3. Participants are required to have a body mass index (BMI) between 18 and 30 kg/m^2.
Exclusion criteria
Exclusion criteria: 1. Heart failure with NYHA functional class III or IV who are scheduled to undergo trauma-related or emergency surgery; 2. Unstable coronary artery disease; severe renal impairment (estimated glomerular filtration rate < 30 ml/min/1.73 m²); significant liver function abnormalities (alanine aminotransferase or aspartate aminotransferase levels more than twice the upper limit of normal); 3. Presence of coagulation disorders or failure to discontinue anticoagulant drugs (such as warfarin, rivaroxaban, dabigatran, etc.) in accordance with institutional perioperative management guidelines; 4. Chronic pain syndrome (such as complex regional pain syndrome, reflex sympathetic dystrophy) or long-term use of opioids (defined as continuous use for more than 3 months, or daily oral morphine equivalent dose exceeding 5 mg for at least 1 month); 5. Current or within the last 2 months, history of alcohol abuse; uncontrolled mental illness (such as schizophrenia, severe anxiety disorder); 6. Known allergy to amide-type local anesthetics or any drug involved in the study; 7. Presence of contraindications to study drugs; 8. Pregnant or lactating women, and those planning to become pregnant during the study period; 9. Inability or refusal to sign the written informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The area under the curve (AUC) of the numeric rating scale (NRS) pain score at rest 48 hours after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| The NRS scores at multiple time points within 72 hours after surgery ;The indicators related to functional recovery include the volume of thoracic drainage fluid, the time of chest tube removal, the length of stay in the Post-Anesthesia Care Unit (PACU);The occurrence of postoperative pulmonary complications (PPCs) ;Other postoperative complications were also monitored and recorded. Including New-onset atrial fibrillation (NOAF), severe ventricular arrhythmia, and deep venous thrombosis (DVT) DVT, pulmonary embolism (PE) and intestinal obstruction. ;Postoperative sufentanil consumption;The time of first getting out of bed for activity and the frequency of rescue analgesia use.;The quality of postoperative recovery was evaluated using the validated Recovery Quality-40 scale.;Preoperative baseline, postoperative day 1 (POD-1), and postoperative day 2 (POD-2).;Postoperative nausea and vomiting;Systemic inflammatory response was evaluated by measuring C-reactive protein (CRP) on the day before surgery (i.e., one day before the operation), and by determining the levels of CRP, procalcitonin (PCT), and interleukin-6 (IL-6) on the first postoperative day.; | — |
Countries
China
Contacts
Public ContactWei Deng
The First Affiliated Hospital of Nanchang University
Outcome results
None listed